How Oral Dersimelagon Stimulates Melanin Production
For individuals researching how pigmentation pathways operate without ultraviolet radiation, oral melanocortin agonists represent a notable area of scientific inquiry. Traditional tanning relies on solar radiation to damage cell DNA and trigger pigment production, carrying distinct oncogenic hazards. Understanding how new compounds activate these biological targets in laboratory settings helps clarify how pigment pathways work. Anyone researching skin pigmentation should always consult a board-certified dermatologist, especially because unregulated peptides purchased online pose serious health hazards.
What is dersimelagon, and how was it evaluated in the 2022 study?
Dersimelagon, also identified in laboratory investigations as MT-7117, is a novel oral melanocortin 1 receptor agonist. In a 2022 research paper published in Skin Health and Disease, researchers investigated the binding properties, downstream cellular signalling, and pigment-inducing effects of this compound across multiple laboratory models.
The investigators examined how dersimelagon selectively bound to recombinant melanocortin receptors compared to natural and synthetic reference peptides. The reference comparators evaluated in the laboratory were alpha melanocyte-stimulating hormone (αMSH), which is a tridecapeptide known to stimulate skin pigmentation, and [Nle4, D-Phe7]-αMSH (NDP-αMSH). The primary objective was to observe whether an orally bioavailable small molecule could selectively trigger receptor signalling and produce genuine eumelanin without requiring ultraviolet light.
How does dersimelagon trigger cellular pigment pathways?
In human biology, the melanocortin 1 receptor (MC1R) sits on the surface of melanocytes, the specialized cells responsible for creating pigment. When this receptor is engaged, it stimulates the internal production of eumelanin, the darker form of melanin that absorbs light. To understand how this fits into overall human biology, readers can review MC1R and Skin Pigment: How Tanning Works in the Body.
According to the 2022 study in Skin Health and Disease, dersimelagon demonstrated its highest affinity for human MC1R relative to the other melanocortin receptors tested. When the compound binds to MC1R, it activates an intracellular cascade, stimulating the production of cyclic adenosine 3', 5'-monophosphate (cAMP). In laboratory assays using the B16F1 mouse melanoma cell line, dersimelagon stimulated melanin production in a concentration-dependent manner, showing agonistic activity across human, mouse, and cynomolgus monkey receptors with EC50 values falling in the nanomolar range.
What happened in animal models without ultraviolet light exposure?
Beyond isolated cell cultures, the researchers tested whether repeated oral administration could trigger physical pigmentation changes without UV lamps or sun exposure. The in vivo experiments relied on oral gavage in two distinct animal models:
- C57BL/6J-Ay/+ mice: Repeat administration of MT-7117 produced significant darkening of the animals' coat colour.
- Cynomolgus monkeys: Daily oral administration induced significant skin pigmentation across the evaluated skin sites.
- Pigment reversibility: Following the complete cessation of dersimelagon administration in monkeys, the researchers observed complete reversibility of the induced skin pigmentation.
This reversibility is an important pharmacological finding, demonstrating that the stimulation of melanocytes was dependent on continued receptor engagement rather than permanent alterations to cellular genetics.
What are the study limits and medical goals for this compound?
While the findings provide clear molecular insights, readers must interpret this work within its proper scientific context. This was a single preclinical investigation relying on cell cultures and animal models. Laboratory responses in rodent cell lines and monkeys do not automatically reflect identical clinical outcomes or complete safety profiles in human populations.
Furthermore, dersimelagon is being investigated for serious photodermatoses, specifically rare genetic disorders such as erythropoietic protoporphyria and X-linked protoporphyria, where patients experience intense phototoxic skin reactions upon light exposure. For more on the clinical framework surrounding these disorders, see our review on Dersimelagon in Protoporphyria: Evidence and Research Limits. Preclinical work on targeted medical agonists should never be confused with unapproved tanning injections or unregulated products marketed on the internet, which lack regulatory oversight and carry severe systemic risks.
Sources
PubMed: Melanogenic effect of dersimelagon (MT-7117), a novel oral melanocortin 1 receptor agonist.
Published October 31, 2026. Sources are linked in the text. See our Medical Disclaimer.